PillRx only · Injection · Intravenous
Morphine Sulfate
Morphine Sulfate
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US7 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$2.323
Latest avg · Jul 22, 2026
+2%
Since Feb 19, 2025
3
Active US suppliers
86%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
46K
Rx · 2026 Q1
109K
Units dispensed
+20%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | unknown | 5 | SUPPLYING |
| Civica, Inc. | unknown | 1 | SUPPLYING |
| International Medication Systems, Limited | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Dec 6, 2018SHORTAGEDrug shortage: Morphine Sulfate Injection (Amphastar Pharmaceuticals, Inc.)
Morphine Sulfate Injection — reported in shortage by Amphastar Pharmaceuticals, Inc.. Therapeutic category: Analgesia/Addiction.
- Nov 3, 2017SHORTAGEDrug shortage: Morphine Sulfate Injection (Hikma Pharmaceuticals USA, Inc.)
Morphine Sulfate Injection — reported in shortage by Hikma Pharmaceuticals USA, Inc.. Therapeutic category: Analgesia/Addiction.